90 related articles for article (PubMed ID: 25041811)
1. Population pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 in healthy volunteers following single and multiple dose regimens.
An G; Liu W; Katz DA; Marek GJ; Awni W; Dutta S
Biopharm Drug Dispos; 2014 Oct; 35(7):417-29. PubMed ID: 25041811
[TBL] [Abstract][Full Text] [Related]
2. Effect of ketoconazole on the pharmacokinetics of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor ABT-384 and its two active metabolites in healthy volunteers: population analysis of data from a drug-drug interaction study.
An G; Liu W; Katz DA; Marek G; Awni W; Dutta S
Drug Metab Dispos; 2013 May; 41(5):1035-45. PubMed ID: 23431112
[TBL] [Abstract][Full Text] [Related]
3. Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384.
Katz DA; Liu W; Locke C; Jacobson P; Barnes DM; Basu R; An G; Rieser MJ; Daszkowski D; Groves F; Heneghan G; Shah A; Gevorkyan H; Jhee SS; Ereshefsky L; Marek GJ
Transl Psychiatry; 2013 Aug; 3(8):e295. PubMed ID: 23982627
[TBL] [Abstract][Full Text] [Related]
4. Clinical Safety, Pharmacokinetics, and Pharmacodynamics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor ABT-384 in Healthy Volunteers and Elderly Adults.
Liu W; Katz DA; Locke C; Daszkowski D; Wang Y; Rieser MJ; Awni W; Marek GJ; Dutta S
Clin Pharmacol Drug Dev; 2013 Apr; 2(2):133-51. PubMed ID: 27121668
[TBL] [Abstract][Full Text] [Related]
5. Small-molecule compounds exhibiting target-mediated drug disposition - A case example of ABT-384.
An G; Liu W; Dutta S
J Clin Pharmacol; 2015 Oct; 55(10):1079-85. PubMed ID: 25931139
[TBL] [Abstract][Full Text] [Related]
6. A Target-Mediated Drug Disposition Model to Explain Nonlinear Pharmacokinetics of the 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor SPI-62 in Healthy Adults.
Wu N; Katz DA; An G
J Clin Pharmacol; 2021 Nov; 61(11):1442-1453. PubMed ID: 34110620
[TBL] [Abstract][Full Text] [Related]
7. Pharmacokinetics and pharmacodynamics of single and multiple oral doses of a novel 5-lipoxygenase inhibitor (ABT-761) in healthy volunteers.
Wong SL; Drajesk J; Chang M; Lanni C; Witt G; Hansen R; Awni WM
Clin Pharmacol Ther; 1998 Mar; 63(3):324-31. PubMed ID: 9542476
[TBL] [Abstract][Full Text] [Related]
8. Pharmacokinetic-pharmacodynamic studies of the 11β-hydroxysteroid dehydrogenase type 1 inhibitor MK-0916 in healthy subjects.
Wright DH; Stone JA; Crumley TM; Wenning L; Zheng W; Yan K; Yang AY; Sun L; Cilissen C; Ramael S; Hermanowski-Vosatka A; Langdon RB; Gottesdiener KM; Wagner JA; Lai E
Br J Clin Pharmacol; 2013 Dec; 76(6):917-31. PubMed ID: 23594227
[TBL] [Abstract][Full Text] [Related]
9. Single- and multiple-dose pharmacokinetics, safety, and tolerability of the selective alpha7 neuronal nicotinic receptor agonist, ABT-107, in healthy human volunteers.
Othman AA; Lenz RA; Zhang J; Li J; Awni WM; Dutta S
J Clin Pharmacol; 2011 Apr; 51(4):512-26. PubMed ID: 20495134
[TBL] [Abstract][Full Text] [Related]
10. Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors.
Rohde JJ; Pliushchev MA; Sorensen BK; Wodka D; Shuai Q; Wang J; Fung S; Monzon KM; Chiou WJ; Pan L; Deng X; Chovan LE; Ramaiya A; Mullally M; Henry RF; Stolarik DF; Imade HM; Marsh KC; Beno DW; Fey TA; Droz BA; Brune ME; Camp HS; Sham HL; Frevert EU; Jacobson PB; Link JT
J Med Chem; 2007 Jan; 50(1):149-64. PubMed ID: 17201418
[TBL] [Abstract][Full Text] [Related]
11. Linagliptin, a dipeptidyl peptidase-4 inhibitor in development for the treatment of type 2 diabetes mellitus: a Phase I, randomized, double-blind, placebo-controlled trial of single and multiple escalating doses in healthy adult male Japanese subjects.
Sarashina A; Sesoko S; Nakashima M; Hayashi N; Taniguchi A; Horie Y; Graefe-Mody EU; Woerle HJ; Dugi KA
Clin Ther; 2010 Jun; 32(6):1188-204. PubMed ID: 20637971
[TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetics and pharmacodynamics of AR9281, an inhibitor of soluble epoxide hydrolase, in single- and multiple-dose studies in healthy human subjects.
Chen D; Whitcomb R; MacIntyre E; Tran V; Do ZN; Sabry J; Patel DV; Anandan SK; Gless R; Webb HK
J Clin Pharmacol; 2012 Mar; 52(3):319-28. PubMed ID: 21422238
[TBL] [Abstract][Full Text] [Related]
13. Population Target-Mediated Pharmacokinetic/Pharmacodynamic Modeling to Evaluate SPI-62 Exposure and Hepatic 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition in Healthy Adults.
Wu N; Katz DA; An G
Clin Pharmacokinet; 2023 Sep; 62(9):1275-1288. PubMed ID: 37452998
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetics of the TRPV1 antagonist ABT-102 in healthy human volunteers: population analysis of data from 3 phase 1 trials.
Othman AA; Nothaft W; Awni WM; Dutta S
J Clin Pharmacol; 2012 Jul; 52(7):1028-41. PubMed ID: 21566201
[TBL] [Abstract][Full Text] [Related]
15. Population pharmacokinetics and exposure-uric acid analyses after single and multiple doses of ABT-639, a calcium channel blocker, in healthy volunteers.
An G; Liu W; Duan WR; Nothaft W; Awni W; Dutta S
AAPS J; 2015 Mar; 17(2):416-26. PubMed ID: 25567367
[TBL] [Abstract][Full Text] [Related]
16. Safety, Pharmacokinetics, and Pharmacodynamics of ASP3662, a Novel 11β-Hydroxysteroid Dehydrogenase Type 1 Inhibitor, in Healthy Young and Elderly Subjects.
Bellaire S; Walzer M; Wang T; Krauwinkel W; Yuan N; Marek GJ
Clin Transl Sci; 2019 May; 12(3):291-301. PubMed ID: 30740895
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetics of ABT-122, a TNF-α- and IL-17A-Targeted Dual-Variable Domain Immunoglobulin, in Healthy Subjects and Patients with Rheumatoid Arthritis: Results from Three Phase I Trials.
Khatri A; Goss S; Jiang P; Mansikka H; Othman AA
Clin Pharmacokinet; 2018 May; 57(5):613-623. PubMed ID: 28744796
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
Hübner R; Högemann AM; Sunzel M; Riddell JG
J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
[TBL] [Abstract][Full Text] [Related]
19. Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.
Olson S; Aster SD; Brown K; Carbin L; Graham DW; Hermanowski-Vosatka A; LeGrand CB; Mundt SS; Robbins MA; Schaeffer JM; Slossberg LH; Szymonifka MJ; Thieringer R; Wright SD; Balkovec JM
Bioorg Med Chem Lett; 2005 Oct; 15(19):4359-62. PubMed ID: 16039856
[TBL] [Abstract][Full Text] [Related]
20. Safety, tolerability and pharmacokinetics of the histamine H3 receptor antagonist, ABT-288, in healthy young adults and elderly volunteers.
Othman AA; Haig G; Florian H; Locke C; Zhang J; Dutta S
Br J Clin Pharmacol; 2013 May; 75(5):1299-311. PubMed ID: 23016924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
